Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Actinogen Medical ( (AU:ACW) ) has provided an announcement.
Actinogen Medical has notified the ASX of a proposed placement or similar issue of up to 15,880,953 new ordinary fully paid shares, with a planned issue date of 18 March 2026. The move signals the company’s intention to raise additional equity capital, which may be used to support its ongoing operations and strategic initiatives, and could lead to share dilution for existing investors while potentially strengthening its balance sheet and funding capacity.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is an ASX-listed biotechnology company (code: ACW) focused on developing medical therapies, with its ordinary fully paid shares traded on the Australian Securities Exchange. The company operates in the healthcare and life sciences sector, using capital markets to fund its research, development, and commercialisation activities.
YTD Price Performance: -26.23%
Average Trading Volume: 5,840,451
Technical Sentiment Signal: Hold
Current Market Cap: A$143.6M
Learn more about ACW stock on TipRanks’ Stock Analysis page.